Acclimate Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.60 M
as on 03-12-2024
- Paid Up Capital ₹ 0.60 M
as on 03-12-2024
- Company Age 14 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.28 M
as on 03-12-2024
- Revenue -45.56%
(FY 2022)
- Profit 85.75%
(FY 2022)
- Ebitda 72.95%
(FY 2022)
- Net Worth -13.97%
(FY 2022)
- Total Assets -52.98%
(FY 2022)
About Acclimate Pharmaceuticals
The Corporate was formerly known as Acclimate Management Consultants Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.60 M and a paid-up capital of Rs 0.60 M.
The company has closed loans amounting to ₹1.28 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Ujwala Pote and Appa Makhar serve as directors at the Company.
- CIN/LLPIN
U15137PN2010PTC136578
- Company No.
136578
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Jun 2010
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Pune
Industry
Company Details
- Location
Pune, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Acclimate Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ujwala Pote  | Director | 25-Mar-2024 | Current |
| Appa Makhar | Director | 25-Mar-2024 | Current |
Financial Performance of Acclimate Pharmaceuticals.
Acclimate Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 45.56% decrease. The company also saw a substantial improvement in profitability, with a 85.75% increase in profit. The company's net worth observed a substantial decline by a decrease of 13.97%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Acclimate Pharmaceuticals?
In 2019, Acclimate Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sri Sai Grihnirman & Residency Private LimitedActive 6 years 3 monthsUjwala Pote is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Idbi Bank Limited Creation Date: 28 Apr 2017 | ₹1.28 M | Satisfied |
How Many Employees Work at Acclimate Pharmaceuticals?
Unlock and access historical data on people associated with Acclimate Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Acclimate Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Acclimate Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
